Edwards Lifesciences (EW)
(Delayed Data from NYSE)
$68.12 USD
+1.62 (2.44%)
Updated Aug 15, 2024 04:00 PM ET
After-Market: $68.12 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$68.12 USD
+1.62 (2.44%)
Updated Aug 15, 2024 04:00 PM ET
After-Market: $68.12 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth D Momentum F VGM
Zacks News
Baxter's (BAX) ST Set Receives FDA Nod, to Boost Patient Outcome
by Zacks Equity Research
Baxter's (BAX) ST Set is expected to improve treatments in an acute care environment.
Edwards Lifesciences (EW) Stock Moves -0.05%: What You Should Know
by Zacks Equity Research
In the latest trading session, Edwards Lifesciences (EW) closed at $120.22, marking a -0.05% move from the previous day.
HOLX vs. EW: Which Stock Is the Better Value Option?
by Zacks Equity Research
HOLX vs. EW: Which Stock Is the Better Value Option?
Here's Why You Should Retain Merit Medical (MMSI) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Merit Medical (MMSI) owing to its strong product portfolio.
Shockwave Medical's (SWAV) New Launch to Lower IVL Treatment Time
by Zacks Equity Research
Shockwave Medical's (SWAV) latest global commercial launch is expected to serve a more diverse patient pool.
DexCom's (DXCM) Upcoming Launch to Boost Diabetes Management
by Zacks Equity Research
DexCom's (DXCM) upcoming launch of Dexcom ONE CGM can help people in the U.K. to manage diabetes.
Here's Why You Should Hold on to Stryker (SYK) Stock for Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic-arm assisted surgery platform, Mako, and broad product portfolio. However, pricing pressure remains a concern.
Strength Seen in Alphatec (ATEC): Can Its 12.1% Jump Turn into More Strength?
by Zacks Equity Research
Alphatec (ATEC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Edwards Lifesciences (EW) Gets FDA Nod for MITRIS RESILIA Valve
by Zacks Equity Research
Edwards Lifesciences' (EW) MITRIS RESILIA valve has been designed to resemble the appearance and function of the native mitral valve.
Edwards Lifesciences (EW) Up 7.5% Since Q4 Earnings Release
by Zacks Equity Research
Edwards Lifesciences' (EW) stock rallies on impressive fourth-quarter performance and bullish 2022 guidance.
The Zacks Analyst Blog Highlights Visa, Novartis, Deere & Company, Airbnb, and Edwards Lifesciences
by Zacks Equity Research
Visa, Novartis, Deere & Company, Airbnb, and Edwards Lifesciences have been included in this Analyst Blog.
Top Stock Reports for Visa, Novartis & Deere
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), Novartis AG (NVS), and Deere & Company (DE).
Delcath Systems, Inc. (DCTH) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Delcath Systems, Inc. (DCTH) delivered earnings and revenue surprises of 25.81% and 285.38%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain Edwards Lifesciences (EW) Now
by Zacks Equity Research
Investors are optimistic about Edwards Lifesciences' (EW) robust segmental performance and growing product uptake.
Edwards Lifesciences (EW) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Edwards Lifesciences (EW) closed at $102.25, marking a -1.16% move from the previous day.
Why Edwards Lifesciences (EW) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Edwards Lifesciences (EW) Stock Moves -0.68%: What You Should Know
by Zacks Equity Research
Edwards Lifesciences (EW) closed at $111.61 in the latest trading session, marking a -0.68% move from the prior day.
Why Is Edwards Lifesciences (EW) Up 7.5% Since Last Earnings Report?
by Zacks Equity Research
Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Edwards Lifesciences (EW) Stock Moves -0.58%: What You Should Know
by Zacks Equity Research
Edwards Lifesciences (EW) closed the most recent trading day at $105.33, moving -0.58% from the previous trading session.
Here's Why You Should Retain Edwards Lifesciences (EW) Stock
by Zacks Equity Research
Investors are optimistic about Edwards Lifesciences (EW) on continued strong adoption of the SAPIEN 3 Ultra platform and the PASCAL system.
The Zacks Analyst Blog Highlights: AbbVie, Edwards Lifesciences and Johnson Controls International
by Zacks Equity Research
AbbVie, Edwards Lifesciences and Johnson Controls International are included in this analyst blog.
Edwards Lifesciences (EW) Q4 Earnings Fall Shy of Estimates
by Zacks Equity Research
Strong sales growth across all four product groups along with increased adoption of the PASCAL platform drove Edwards Lifesciences' (EW) fourth-quarter revenues.
Top Analyst Reports for AbbVie, Edwards Lifesciences & Johnson Controls
by Mark Vickery
Today's Research Daily features new research reports on 12 major stocks, including AbbVie Inc. (ABBV), Edwards Lifesciences Corporation (EW), and Johnson Controls International plc (JCI).
Edwards Lifesciences (EW) Lags Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Edwards Lifesciences (EW) delivered earnings and revenue surprises of -7.27% and 1.03%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
5 Big Cap Earnings All Stars to Watch This Week
by Tracey Ryniec
Get ready. Tesla and Microsoft are among the tech titans that will report. Can they beat again?